Traditional, complementary and integrative medicine therapies for the treatment of mild/moderate acute COVID-19: protocol for a systematic review and network meta-analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BMJ Publishing Group Ltd, 2011-
    • Subject Terms:
      Complementary Therapies*/methods ; COVID-19*/diagnosis ; COVID-19*/therapy ; Integrative Medicine*/methods; Humans ; Network Meta-Analysis ; Pandemics/prevention & control ; Research Design ; SARS-CoV-2 ; Systematic Reviews as Topic
    • Abstract:
      Background: Increasing evidence has emerged for traditional, complementary and integrative medicine (TCIM) to treat COVID-19 which requires systematic summaries of the net benefits of interventions against standard care and one another. The study aims to conduct a systematic review and network meta-analysis (NMA) regarding TCIM therapies for treating mild/moderate acute COVID-19, potentially informing the WHO guideline development and clinical decision-making.
      Methods and Analysis: We will search Embase, MEDLINE, Virtual Health Library on Traditional Complementary and Integrative Medicine, Cochrane Central Register of Controlled Trials, WHO's International Clinical Trials Registry Platform with additional searches of Chinese and Korean literature sources for randomised controlled trials comparing TCIM with placebo, standard care, no treatment or with an alternate type of TCIM to treat COVID-19. We will limit the search dates from 2020 to 28 March 2024. Reviewers will, in duplicate, screen eligible articles, extract data and evaluate the risk of bias. We will conduct frequentist network meta-analyses for network comparisons and each outcome. We will assess the certainty of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach and classify interventions from most to least effective or harmful.
      Ethics and Dissemination: This NMA is based on the existing trials and data which is not subject to ethical approval. We will publish the NMA in a peer-reviewed journal. This may provide methodological reference and clinical evidence for TCIM on future epidemic-prone diseases.
      Prospero Registration Number: CRD42024517321.
      Competing Interests: Competing interests: We would like to disclose that Dr. Guyatt Gordon and Dr. Thabane Lehana are listed as members of the Editorial Board of BMJ Open, as noted on their website (https://bmjopen.bmj.com/pages/editorial-board). This association has been declared in accordance with the journal’s submission policies. All other authors have no potential conflicts of interest to declare related to this submission.
      (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
    • References:
      Control Clin Trials. 1986 Sep;7(3):177-88. (PMID: 3802833)
      BMJ. 2021 Apr 26;373:n949. (PMID: 33903131)
      Res Social Adm Pharm. 2022 Mar;18(3):2524-2528. (PMID: 33992585)
      BMJ. 2015 Jan 02;350:g7647. (PMID: 25555855)
      BMC Med Res Methodol. 2013 Mar 09;13:35. (PMID: 23496991)
      BMJ. 2020 Nov 11;371:m3900. (PMID: 33177059)
      Int J Health Plann Manage. 2020 Sep;35(5):1240-1245. (PMID: 32557820)
      Stat Med. 2006 Oct 30;25(20):3443-57. (PMID: 16345038)
      J Clin Epidemiol. 2013 Feb;66(2):173-83. (PMID: 23116689)
      J Clin Epidemiol. 2023 Jun;158:70-83. (PMID: 36898507)
      BMJ. 2020 Jul 30;370:m2980. (PMID: 32732190)
      J Clin Epidemiol. 2017 Jul;87:14-22. (PMID: 28529188)
      CMAJ. 2020 Aug 10;192(32):E901-E906. (PMID: 32778601)
      Stata J. 2018 Jul 1;18(3):716-740. (PMID: 30595674)
      Lancet. 2022 Feb 26;399(10327):779-782. (PMID: 35219388)
      BMJ. 2020 Sep 4;370:m3379. (PMID: 32887691)
      Front Med (Lausanne). 2022 May 09;9:884573. (PMID: 35615091)
      BMC Med. 2024 Mar 13;22(1):112. (PMID: 38475826)
      J Am Stat Assoc. 2012 Jun 1;107(498):555-567. (PMID: 23734068)
      J Clin Epidemiol. 2019 Jan;105:60-67. (PMID: 30253217)
      Saudi Pharm J. 2020 Nov;28(11):1326-1332. (PMID: 32904846)
      BMJ. 2023 Jun 27;381:e074495. (PMID: 37369385)
      J Clin Epidemiol. 2022 Dec;152:218-225. (PMID: 36424692)
      BMJ. 2021 Mar 1;372:n526. (PMID: 33649077)
      BMJ. 1997 Sep 13;315(7109):629-34. (PMID: 9310563)
      Res Synth Methods. 2012 Jun;3(2):98-110. (PMID: 26062084)
      Stat Med. 2010 Mar 30;29(7-8):932-44. (PMID: 20213715)
      Res Synth Methods. 2011 Sep;2(3):188-203. (PMID: 26061786)
      BMC Med Res Methodol. 2021 Jun 1;21(1):113. (PMID: 34074239)
      J Clin Epidemiol. 2011 Dec;64(12):1277-82. (PMID: 21802904)
    • Grant Information:
      001 International WHO_ World Health Organization
    • Contributed Indexing:
      Keywords: COVID-19; Complementary Medicine; Network Meta-Analysis; Protocols & guidelines
    • Publication Date:
      Date Created: 20241108 Date Completed: 20241108 Latest Revision: 20241211
    • Publication Date:
      20241211
    • Accession Number:
      PMC11552603
    • Accession Number:
      10.1136/bmjopen-2024-088959
    • Accession Number:
      39515857